VIA
LENZ

Virtus Investment Advisers’s LENZ Therapeutics LENZ Stock Holding History

Virtus Investment Advisers’s Portfolio LENZ Stock Details LENZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-46,542
Closed -$426K – 517
2026
Q1 		$426K Buy
46,542
+8,868
+24% +$125K 0.12% 239
2025
Q4 		$603K Buy
37,674
+33,827
+879% +$986K 0.16% 219
2025
Q3 		$179K Buy
3,847
+668
+21% +$24.6K 0.05% 278
2025
Q2 		$93.2K Sell
3,179
-2,155
-40% -$58.6K 0.03% 362
2025
Q1 		$137K Buy
+5,334
New +$131K 0.04% 359

Other funds holding LENZ

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
AWG
Alpha Wave Global New York $6.24B AUM 59.73% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
7IH
72 Investment Holdings Stamford, Connecticut $50M AUM 647.58% 1-Year Est. Return

Virtus Investment Advisers's LENZ Position: Q2 2026 in Review

Virtus Investment Advisers sold out of LENZ Therapeutics (LENZ) in Q2 2026, closing a stake of 46,542 shares — an estimated $426K sold.

Virtus Investment Advisers first reported a position in LENZ in Q1 2025 and held it in 5 quarters. The position peaked at $603K in Q4 2025. 144 funds tracked by Wall St. Rank hold LENZ as of Q2 2026.

  • Virtus Investment Advisers reported no remaining LENZ Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Virtus Investment Advisers sold 46,542 LENZ Therapeutics shares in Q2 2026, an estimated $426K.
  • Virtus Investment Advisers first reported a position in LENZ Therapeutics in Q1 2025 and held it in 5 quarters.
  • Virtus Investment Advisers's LENZ Therapeutics position peaked at $603K in Q4 2025.
  • 144 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q2 2026.

Based on Virtus Investment Advisers's 13F filing for Q2 2026, filed 11 Aug 2026.